Clinical Trials Browser

Phase 1 × INDUSTRY × Alemtuzumab × Clear all

NCT05557903 2022-09-28

Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL

Phase 1 Unknown

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, T-Cell

NCT00923182 2015-04-30

A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase 1 Completed

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00113048 2014-02-05

Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies

Phase 1 Terminated

Other hematologic neoplasm

Hematologic Neoplasms